MX391963B - Beta-caseina a2 y prevencion de la inflamacion del intestino. - Google Patents

Beta-caseina a2 y prevencion de la inflamacion del intestino.

Info

Publication number
MX391963B
MX391963B MX2019010594A MX2019010594A MX391963B MX 391963 B MX391963 B MX 391963B MX 2019010594 A MX2019010594 A MX 2019010594A MX 2019010594 A MX2019010594 A MX 2019010594A MX 391963 B MX391963 B MX 391963B
Authority
MX
Mexico
Prior art keywords
casein
beta
prevention
intestinal inflammation
inflammation
Prior art date
Application number
MX2019010594A
Other languages
English (en)
Spanish (es)
Other versions
MX2019010594A (es
Inventor
Andrew John Clarke
Malav Suchin Trivedi
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX391963(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2019010594A publication Critical patent/MX2019010594A/es
Publication of MX391963B publication Critical patent/MX391963B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Confectionery (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019010594A 2013-05-31 2014-05-30 Beta-caseina a2 y prevencion de la inflamacion del intestino. MX391963B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829764P 2013-05-31 2013-05-31
PCT/NZ2014/000102 WO2014193248A1 (en) 2013-05-31 2014-05-30 Beta-casein a2 and prevention of inflammation of the bowel

Publications (2)

Publication Number Publication Date
MX2019010594A MX2019010594A (es) 2019-10-15
MX391963B true MX391963B (es) 2025-03-21

Family

ID=51989162

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010594A MX391963B (es) 2013-05-31 2014-05-30 Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX2015016493A MX367794B (es) 2013-05-31 2014-05-30 Beta-caseína a2 y prevención de la inflamación del intestino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015016493A MX367794B (es) 2013-05-31 2014-05-30 Beta-caseína a2 y prevención de la inflamación del intestino.

Country Status (19)

Country Link
US (2) US20160113997A1 (https=)
EP (2) EP3542813A1 (https=)
JP (2) JP6867158B2 (https=)
KR (2) KR102282972B1 (https=)
CN (2) CN105407971B (https=)
AU (2) AU2014271423B2 (https=)
BR (1) BR112015029987A8 (https=)
CA (1) CA2913890C (https=)
CL (1) CL2015003507A1 (https=)
DK (1) DK3003485T3 (https=)
ES (1) ES2742306T3 (https=)
IL (2) IL242833B (https=)
MX (2) MX391963B (https=)
MY (1) MY179497A (https=)
PH (2) PH12015502674B1 (https=)
RU (1) RU2669553C2 (https=)
SG (2) SG10201709509RA (https=)
WO (1) WO2014193248A1 (https=)
ZA (1) ZA201508983B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
MX368912B (es) * 2013-07-12 2019-10-21 A2 Milk Co Ltd Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa.
GB2519101A (en) * 2013-10-09 2015-04-15 Nicoventures Holdings Ltd Electronic vapour provision system
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient
JP7137745B2 (ja) * 2015-05-22 2022-09-15 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼインａ２および抗酸化能
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
WO2017171563A1 (en) 2016-03-30 2017-10-05 The A2 Milk Company Limited Beta-caseins and cognitive function
JP6873234B2 (ja) * 2016-09-30 2021-05-19 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および腸微生物叢
CN109563049B (zh) * 2016-10-14 2022-11-29 豪夫迈·罗氏有限公司 作为eaat3抑制剂的咪唑化合物
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN115708530B (zh) * 2022-11-15 2024-08-09 北大荒完达山乳业股份有限公司 一种促进消化舒适性并稳定血糖的孕产妇配方奶粉及其制备方法
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用
WO2026003044A1 (en) * 2024-06-25 2026-01-02 Ntd Labs, S.L. Casein hydrolysate for treating crohn's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
NZ306584A (en) * 1995-05-16 2000-02-28 Corran Norman Stuart Mclachlan Milk or dairy products derived from animals and which are free of beta casein
AU4266100A (en) * 1995-05-16 2000-10-12 Corran Norman Stuart Mclachlan Food product and process
WO1996036239A1 (en) 1995-05-16 1996-11-21 Corran Norman Stuart Mclachlan Food product and process
US6570060B2 (en) 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
AU771754B2 (en) * 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
NZ516712A (en) * 1999-06-29 2003-10-31 New Zealand Milk Inst Ltd Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
CA2444470A1 (en) * 2001-04-10 2002-10-24 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
US20060280802A1 (en) 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
US7481127B2 (en) 2004-09-27 2009-01-27 Lester William T Continuously variable transmission using oscillating torque and one-way drives
WO2008041219A1 (en) * 2006-10-06 2008-04-10 Kerry Group Services International Limited A milk protein composition and use thereof
US8871276B2 (en) * 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
TWI516269B (zh) * 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
MX368912B (es) * 2013-07-12 2019-10-21 A2 Milk Co Ltd Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa.

Also Published As

Publication number Publication date
AU2018274937B2 (en) 2020-10-29
PH12019550096A1 (en) 2020-02-10
IL262302B (en) 2021-02-28
JP7224242B2 (ja) 2023-02-17
EP3003485B1 (en) 2019-05-15
HK1222362A1 (en) 2017-06-30
IL262302A (en) 2018-11-29
KR20160024884A (ko) 2016-03-07
KR20210094674A (ko) 2021-07-29
JP2019165746A (ja) 2019-10-03
EP3003485A4 (en) 2016-11-30
NZ714912A (en) 2021-06-25
US20200179485A1 (en) 2020-06-11
MY179497A (en) 2020-11-09
AU2014271423B2 (en) 2018-12-20
IL242833B (en) 2019-07-31
PH12015502674A1 (en) 2016-03-07
CA2913890C (en) 2024-09-10
WO2014193248A1 (en) 2014-12-04
DK3003485T3 (da) 2019-08-19
MX367794B (es) 2019-09-06
RU2018131733A3 (https=) 2021-10-29
RU2015153113A (ru) 2017-07-05
CN105407971A (zh) 2016-03-16
CN112316116A (zh) 2021-02-05
BR112015029987A8 (pt) 2021-12-07
AU2014271423A1 (en) 2015-12-24
PH12015502674B1 (en) 2020-02-21
MX2019010594A (es) 2019-10-15
JP2016520611A (ja) 2016-07-14
RU2669553C2 (ru) 2018-10-12
KR102402455B1 (ko) 2022-05-25
ZA201508983B (en) 2017-11-29
CA2913890A1 (en) 2014-12-04
MX2015016493A (es) 2016-08-18
BR112015029987A2 (pt) 2017-07-25
JP6867158B2 (ja) 2021-04-28
CN105407971B (zh) 2020-11-17
CL2015003507A1 (es) 2016-12-16
ES2742306T3 (es) 2020-02-13
SG11201509769QA (en) 2015-12-30
SG10201709509RA (en) 2017-12-28
AU2018274937A1 (en) 2019-01-03
RU2018131733A (ru) 2018-11-08
EP3542813A1 (en) 2019-09-25
EP3003485A1 (en) 2016-04-13
KR102282972B1 (ko) 2021-07-28
US20160113997A1 (en) 2016-04-28
US11911439B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
MX391963B (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
EA201691194A1 (ru) Стимуляторы ргц
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
HRP20182179T1 (hr) 2,3-disupstituirani 1-acil-4-amino-1,2,3,4-tetrahidrokonolin derivati i njihova uporaba kao inhibitora bromodomena
EP3313530A4 (en) 4,6-PYRIMIDINYLENE DERIVATIVES AND USE THEREOF
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PH12016501702A1 (en) Pyrazole amide derivative
CL2017000136A1 (es) Composiciones de azúcar para la formación de comprimidos por compresión directa
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
DE112016003858A5 (de) Laschenkette im Dreilaschenverband
MX2019013642A (es) Compuestos, composiciones y metodos.
EP3175723A4 (en) Men's underwear
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
MX2017007676A (es) Nuevos compuestos.
IL249122A0 (en) History of imidazole- or 4,2,1-triazole and their use
GB2543709A (en) Pharmaceutical agent
MA41125A (fr) Dérivés de 6.7-cyclomorphinane et leur utilisation
DK2942050T3 (da) Spraybar, olieholdig sammensætning baseret på fedtopløselige vitaminer fra gruppe d og anvendelse deraf
JP2016064626A5 (https=)
CR20150352A (es) Nuevas composiciones antifúngicidas
KOCH The Face as Entryway to the Self
TH169357A (th) เบต้า-คาเซอิน a2 และการป้องกันการอักเสบของลำไส้